Rebleeding after Initial Endoscopic Hemostasis in Peptic Ulcer Disease
Journal of Korean Medical Science
;
: 1411-1415, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-23616
ABSTRACT
Endoscopic hemostasis is the first-line treatment for upper gastrointestinal bleeding (UGIB). Although several factors are known to be risk factors for rebleeding, little is known about the use of antithrombotics. We tried to verify whether the use of antithrombotics affects rebleeding rate after a successful endoscopic hemostasis for peptic ulcer disease (PUD). UGIB patients who underwent successful endoscopic hemostasis were included. Rebleeding was diagnosed when the previously treated lesion bled again within 30 days of the initial episode. Of 522 UGIB patients with PUD, rebleeding occurred in 93 patients (17.8%). The rate of rebleeding was higher with aspirin medication (P=0.006) and after a long endoscopic hemostasis (P<0.001). Of all significant variables, procedure time longer than 13.5 min was related to the rate of rebleeding (OR, 2.899; 95% CI, 1.768-4.754; P<0.001) on the logistic regression analysis. The rate of rebleeding after endoscopic hemostasis for PUD is higher in the patients after a long endoscopic hemostasis. Endoscopic hemostasis longer than 13.5 min is related to rebleeding after a successful endoscopic hemostasis for PUD.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Úlcera Péptica
/
Recurrencia
/
Antitrombinas
/
Aspirina
/
Hemostasis Endoscópica
/
Tracto Gastrointestinal Superior
/
Hemorragia
/
Hemorragia Gastrointestinal
Tipo de estudio:
Factores de riesgo
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Journal of Korean Medical Science
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS